COMP <GO>
MAIA vs TELO // REVENUE GROWTH (YOY)
MAIA Biotechnology Inc. (NYSE) VS. Telomir Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: MAIA 2
— TELO 0
■ METRIC PARITY
LAST: $1.10 (-6.78%) • MKT CAP: $72.9M
revenue-growth
—
LAST: $0.94 (-3.01%) • MKT CAP: $71.0M
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MAIA VS. TELO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MAIA | TELO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -5.19% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.2 | 29.3 | +15.85 | MAIA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $72.9M | $71.0M | $1.8M | MAIA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MAIA REV | TELO REV | MAIA GROSS % | TELO GROSS % | MAIA FCF | TELO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$18.8M | -$3.7M |
| FY 2024 | $0 | $0 | — | — | -$15.7M | -$5.1M |
| FY 2023 | — | $0 | — | — | — | -$3.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MAIA // BETA —
TELO // BETA —